Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Equity Average (2016 - 2025)

United Therapeutics' Equity Average history spans 16 years, with the latest figure at $6.8 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 9.1% year-over-year to $6.8 billion; the TTM value through Dec 2025 reached $6.8 billion, up 9.1%, while the annual FY2025 figure was $6.8 billion, 8.94% up from the prior year.
  • Equity Average for Q4 2025 was $6.8 billion at United Therapeutics, down from $6.9 billion in the prior quarter.
  • Across five years, Equity Average topped out at $7.0 billion in Q2 2025 and bottomed at $3.4 billion in Q1 2021.
  • The 5-year median for Equity Average is $5.4 billion (2023), against an average of $5.2 billion.
  • The largest annual shift saw Equity Average grew 4.76% in 2024 before it rose 26.69% in 2025.
  • A 5-year view of Equity Average shows it stood at $3.9 billion in 2021, then grew by 20.16% to $4.7 billion in 2022, then grew by 24.98% to $5.8 billion in 2023, then increased by 7.25% to $6.3 billion in 2024, then rose by 9.1% to $6.8 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Equity Average are $6.8 billion (Q4 2025), $6.9 billion (Q3 2025), and $7.0 billion (Q2 2025).